The new diet drug Acomplia (rimonabant) may assist with some cardiometabolic risk factors, lowering triglycerides and to some extent increasing good cholesterol, a broad review in the journal Circulation suggests Sanofi's new diet drug Acomplia is no more effective than older diet pills in reducing bad cholesterol.

According to Dr.Kishore M. Gadde, a Duke University obesity researcher. "Although some features of metabolic syndrome have been shown to improve modestly, no reduction in LDL-C occurs, although this appears to be the case with all centrally acting antiobesity drugs,"

It was published in the Aug. 28 issue of the prestigious journal "It is rather disappointing that weight loss achieved primarily with the help of centrally acting antiobesity drugs does not lead to reduction in LDL-C (bad cholesterol) in most studies, and rimonabant is yet another example of this," said Gadde. Gadde's also elevates detailed questions about Acomplia's psychiatric side effects -- which he freshly surfaced in the Journal of the American Medical Association -- while final Acomplia is no better for weight loss than "the modest effects observed with presently approved antiobesity drugs."

Niche Business Directory

Favourite Link - A free human edited Directory + Search Engine Perfect SEO tool for increasing your website popularity